The DOI matches its Crossref record; 15 of the 23 references it cites were found in a registry or an index, and 8 are not checked yet.
Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy
Abstract
Purpose: The incidence of prostate cancer is frequent, occurring in almost one-third of men older than 45 years. Only a fraction of the cases reach the stages displaying clinical significance. Despite the advances in our understanding of prostate carcinogenesis and disease progression, our knowledge of this disease is still fragmented. Identification of the genes and patterns of gene expression will provide a more cohesive picture of prostate cancer biology. Patients and Methods: In this study, we performed a comprehensive gene expression analysis on 152 human samples including prostate cancer tissues, prostate tissues adjacent to tumor, and organ donor prostate tissues, obtained from men of various ages, using the Affymetrix (Santa Clara, CA) U95a, U95b, and U95c chip sets (37,777 genes and expression sequence tags). Results: Our results confirm an alteration of gene expression in prostate cancer when comparing with nontumor adjacent prostate tissues. However, our study also indicates that the gene expression pattern in tissues adjacent to cancer is so substantially altered that it resembles a cancer field effect. Conclusion: We also found that gene expression patterns can be used to predict the aggressiveness of prostate cancer using a novel model.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Fundamentals of Biostatistics.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-4-873 · Cited by 4,575
Classical and Modern Regression With Applications.
Steinhorst, R. K., & Myers, R. H. (1988) · Journal of the American Statistical Association · doi:10.2307/2288958 · Cited by 3,690
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang‐Rodriguez, J., Moskaluk, C. A., Frierson, H. F., & Hampton, G. M. (2001) · PubMed · Cited by 856
Latulippe, É., Satagopan, J. M., Smith, A., Scher, H. I., Scardino, P. T., Reuter, V. E., & Gerald, W. L. (2002) · PubMed · Cited by 518
Cited by
Items 101–200 of 761
Dobosy, J. R., Roberts, J. L., Fu, V. X., & Jarrard, D. F. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.10.063 · Cited by 118
PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
Vanaja, D. K., Ballman, K. V., Morlan, B. W., Cheville, J. C., Neumann, R. M., Lieber, M. M., Tindall, D. J., & Young, C. Y. F. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2072 · Cited by 118
Yan, J., Erdem, H., Li, R., Cai, Y., Ayala, G., Ittmann, M., Yu‐Lee, L., Tsai, S. Y., & Tsai, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0955 · Cited by 117
The ATDC (TRIM29) Protein Binds p53 and Antagonizes p53-Mediated Functions
Yuan, Z., Villagra, A., Peng, L., Coppola, D., Glozak, M. A., Sotomayor, E. M., Chen, J., Lane, W. S., & Seto, E. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01023-09 · Cited by 123
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer
Vatapalli, R. J., Sagar, V., Rodríguez, Y., Zhao, J. C., Unno, K., Pamarthy, S., Lysy, B., Anker, J. F., Han, H., Yoo, Y. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18013-7 · Cited by 122
The Landscape of Immune Cells Infiltrating in Prostate Cancer
Wu, Z., Chen, H., Luo, W., Zhang, H., Li, G., Zeng, F., & Deng, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.517637 · Cited by 127
Liu, Q., Russell, M. R., Shahriari, K. S., Jernigan, D. L., Lioni, M., Garcia, F. U., & Fatatis, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3970 · Cited by 111
The clusterin paradigm in prostate and breast carcinogenesis
Rizzi, F., & Bettuzzi, S. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0140 · Cited by 108
Cao, J. P., Chiarelli, C., Richman, O., Zarrabi, K. K., Kozarekar, P., & Zucker, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705759200 · Cited by 107
Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility
Kuo, T.-C., Tan, C., Chang, Y.-W., Hong, C., Lee, W.-J., Chen, M.-W., Jeng, Y., Chiou, J., Yu, P., Chen, P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64044 · Cited by 108
A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer
Matin, F., Jeet, V., Moya, L., Selth, L. A., Chambers, S. K., BioResource, A. P. C., Yeadon, T. M., Saunders, P. T. K., Eckert, A., Heathcote, P. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24424-w · Cited by 114
Expression signatures that correlated with Gleason score and relapse in prostate cancer
Bibikova, M. V., Chudin, E., Arsanjani, A. H., Zhou, L., Wickham‐Garcia, E., Modder, J. K., Kostelec, M., Barker, D. L. A., Downs, T. M., Fan, J., et al. (2007) · Genomics · doi:10.1016/j.ygeno.2007.02.005 · Cited by 110
Hypomethylation of Intragenic LINE-1 Represses Transcription in Cancer Cells through AGO2
Aporntewan, C., Phokaew, C., Piriyapongsa, J., Ngamphiw, C., Ittiwut, C., Tongsima, S., & Mutirangura, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017934 · Cited by 122
Stylianou, N., Lehman, M., Wang, C., Fard, A. T., Rockstroh, A., Fazli, L., Jovanovic, L., Ward, M. S., Sadowski, M. C., Kashyap, A. S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0488-5 · Cited by 106
EARLY IDENTIFICATION OF INDIVIDUALS WITH PROSTATE CANCER IN NEGATIVE BIOPSIES
Dhir, R., Vietmeier, B. N., Arlotti, J. A., Acquafondata, M. B., Landsittel, D. P., MASTERSON, R., & Getzenberg, R. H. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000116545.94813.27 · Cited by 102
Self-citationNanni, S., Priolo, C., Grasselli, A., D’Eletto, M., Merola, R., Moretti, F., Gallucci, M., Carli, P. D., Sentinelli, S., Cianciulli, A. M., et al. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0098 · Cited by 102
Zhang, C., Wang, L., Wu, D., Chen, H., Chen, Z., Thomas‐Ahner, J. M., Zynger, D. L., Eeckhoute, J., Yu, J., Luo, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1882 · Cited by 107
Self-citationmiR-539 inhibits prostate cancer progression by directly targeting SPAG5
Zhang, H., Li, S., Yang, X., Qiao, B., Zhang, Z., & Xu, Y. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0337-8 · Cited by 99
Large-scale integration of cancer microarray data identifies a robust common cancer signature
Xu, L., Geman, D., & Winslow, R. L. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-275 · Cited by 106
The Aurora-A/TPX2 complex: A novel oncogenic holoenzyme?
Asteriti, I. A., Rensen, W. M., Lindon, C., Lavia, P., & Guarguaglini, G. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.08.001 · Cited by 98
MetaQC: objective quality control and inclusion/exclusion criteria for genomic meta-analysis
Kang, D., Sibille, E. L., Kaminski, N., & Tseng, G. C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr1071 · Cited by 102
Eddy, J. A., Hood, L., Price, N. D., & Geman, D. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000792 · Cited by 96
The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression
Chakravarthi, B. V. S. K., Pathi, S. S., Goswami, M. T., Cieslik, M. P., Zheng, H., Nallasivam, S., Arekapudi, S. R., Jing, X., Siddiqui, J., Athanikar, J. N., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2208 · Cited by 99
Tan, M.-K. M., Lim, H.-J., & Harper, J. W. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05746-11 · Cited by 94
Long, Q., Johnson, B. A., Osunkoya, A. O., Lai, Y., Zhou, W., Abramovitz, M., Xia, M., Bouzyk, M., Nam, R. K., Sugar, L., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.03.008 · Cited by 93
Alla, V., Kowtharapu, B. S., Engelmann, D., Emmrich, S., Schmitz, U., Steder, M., & Pützer, B. M. (2012) · Cell Cycle · doi:10.4161/cc.21476 · Cited by 92
He, X., Ota, T., Liu, P., Su, C., CHIEN, J. R., & Shridhar, V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3557 · Cited by 98
Cai, L., Tsai, Y., Wang, P., Wang, J., Li, D., Fan, H., Zhao, Y., Bareja, R., Lu, R., Wilson, E. M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.029 · Cited by 95
Gust, K. M., Hofer, M. D., Perner, S., Kim, R., Chinnaiyan, A. M., Varambally, S., Möller, P., Rinnab, L. J., Rubin, M. A., Greiner, J., et al. (2009) · Neoplasia · doi:10.1593/neo.09694 · Cited by 90
TRIM29 negatively regulates p53 via inhibition of Tip60
Sho, T., Tsukiyama, T., Sato, T. Z., Kondo, T., Cheng, J., Saku, T., Asaka, M., & Hatakeyama, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.018 · Cited by 94
Moscat, J., Díaz-Meco, M. T., & Wooten, M. W. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.119 · Cited by 98
Epigenetic Inactivation of the Potential Tumor Suppressor Gene FOXF1 in Breast Cancer
Lo, P., Lee, J. S., Liang, X., Han, L., Mori, T., Fackler, M. J., Sadik, H., Argani, P., Pandita, T. K., & Sukumar, S. V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1576 · Cited by 87
Androgen-Dependent Repression of ERRγ Reprograms Metabolism in Prostate Cancer.
Audet-walsh, É., Yee, T., McGuirk, S., Vernier, M., Ouellet, C., St.-Pierre, J., & Giguère, V. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1204 · Cited by 76
GAPDH: A common housekeeping gene with an oncogenic role in pan-cancer
Wang, J., Yu, X., Cao, X., Tan, L., Jia, B., Chen, R., & Li, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.07.034 · Cited by 91
Mawji, I. A., Simpson, C. D., Hurren, R., Gronda, M., Williams, M. A., Filmus, J., Jonkman, J. E. N., Costa, R. S. D., Wilson, B. C., Thomas, M. P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk182 · Cited by 86
PEG10 as an oncogene: expression regulatory mechanisms and role in tumor progression
Xie, T., Pan, S., Zheng, H., Luo, Z., Tembo, K. M., Jamal, M., Yu, Z., Yu, Y., Xia, J., Yin, Q., et al. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0610-3 · Cited by 92
Self-citationLi, Y., Yang, J., Luo, J., Dedhar, S., & Liu, Y. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006030236 · Cited by 86
Self-citationZhang, S., Wang, X., Osunkoya, A. O., Iqbal, S. A., Wang, Y., Chen, Z., Müller, S., Chen, Z., Josson, S., Coleman, I. M., et al. (2011) · Oncogene · doi:10.1038/onc.2011.199 · Cited by 85
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer
Yu, J., Cao, Q., Yu, J., Wu, L., Dallol, A., Li, J., Chen, G., Grasso, C. S., Cao, X., Lonigro, R. J., et al. (2010) · Oncogene · doi:10.1038/onc.2010.269 · Cited by 85
Heterochromatin protein 1α: a hallmark of cell proliferation relevant to clinical oncology
de Koning, L., Savignoni, A., Boumendil, C., Rehman, H., Asselain, B. J. R., Sastre‐Garau, X., & Almouzni, G. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900022 · Cited by 102
Cistromics of hormone-dependent cancer
Lupien, M., & Brown, M. A. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0038 · Cited by 85
Shao, Y., Ye, G., Ren, S., Piao, H., Zhao, X., Lu, X., Wang, F., Ma, W., Li, J. X., Yin, P., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31313 · Cited by 89
TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis
Singh, R., Karri, D., Shen, H., Shao, J., Dasgupta, S., Huang, S., Edwards, D. P., Ittmann, M., O’Malley, B. W., & Yi, P. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96060 · Cited by 85
Gene expression of forkhead transcription factors in the normal and diseased human prostate
van der Heul-Nieuwenhuijsen, L., Dits, N. F. J., & Jenster, G. W. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08351.x · Cited by 84
WSB1 promotes tumor metastasis by inducing pVHL degradation
Kim, J. J., Lee, S. B., Jang, J., Yi, S.-Y., Kim, S.-H., Han, S.-A., Lee, J.-M., Tong, S.-Y., Vincelette, N. D., Gao, B., et al. (2015) · Genes & Development · doi:10.1101/gad.268128.115 · Cited by 83
Duan, L., Rai, G., Roggero, C. M., Zhang, Q.-J., Wei, Q., Ma, S. H., Zhou, Y., Santoyo, J., Martínez, E. D., Xiao, G., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.08.007 · Cited by 83
Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer
Smith, S. C., Oxford, G., Baras, A. S., Owens, C. R., Havaleshko, D. M., Brautigan, D. L., Safo, M. K., & Theodorescu, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2419 · Cited by 90
Chen, R., Zeng, X., Zhang, R., Huang, J., Kuang, X., Yang, J., Liu, J., Tawfik, O. W., Thrasher, J. B., & Li, B. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.05.011 · Cited by 82
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D
Komura, K., Yoshikawa, Y., Shimamura, T., Chakraborty, G., Gerke, T. A., Hinohara, K., Chadalavada, K., Jeong, S. H., Armenia, J., Du, S.-Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96769 · Cited by 84
Schörghofer, D., Kinslechner, K., Preitschopf, A., Schütz, B., Röhrl, C., Hengstschläger, M., Stangl, H., & Mikula, M. (2015) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-015-0087-z · Cited by 84
Genome-Wide Analysis of the Homeobox C6 Transcriptional Network in Prostate Cancer
McCabe, C. D., Spyropoulos, D. D., Martin, D., & Moreno, C. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5843 · Cited by 81
The Twist Box Domain Is Required for Twist1-induced Prostate Cancer Metastasis
Gajula, R. P., Chettiar, S. T., Williams, R. D., Thiyagarajan, S., Katō, Y., Aziz, K., Wang, R., Gandhi, N. S., Wild, A. T., Vesuna, F., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0218-t · Cited by 88
Novel Fusion Transcripts Associate with Progressive Prostate Cancer
Yu, Y. P., Ding, Y., Chen, Z., Liu, S., Michalopoulos, A., Chen, R., Gulzar, Z. G., Yang, B., Cieply, K. M., Luvison, A., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.06.025 · Cited by 80
Self-citationMeta-analytic principal component analysis in integrative omics application
Kim, S., Kang, D., Huo, Z., Park, Y., & Tseng, G. C. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx765 · Cited by 79
Feature Selection and Molecular Classification of Cancer Using Genetic Programming
Yu, J., Yu, J., Almal, A. A., Dhanasekaran, S. M., Ghosh, D., Worzel, W. P., & Chinnaiyan, A. M. (2007) · Neoplasia · doi:10.1593/neo.07121 · Cited by 79
Sayani, A., Bueno-de-Mesquita, J. M., & van de Vijver, M. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0587 · Cited by 89
Hansel, D. E., Nakayama, M., Luo, J., Abukhdeir, A. M., Park, B. H., Bieberich, C. J., Hicks, J. L., Eisenberger, M. A., Nelson, W. G., Mostwin, J. L., et al. (2009) · The Prostate · doi:10.1002/pros.20910 · Cited by 78
Self-citationMMSET is overexpressed in cancers: Link with tumor aggressiveness
Kassambara, A., Klein, B., & Moreaux, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.12.093 · Cited by 77
Karacosta, L., Foster, B., Azabdaftari, G., Feliciano, D. M., & Edelman, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.370783 · Cited by 72
EXPRESSION OF A NOVEL BIOMARKER, EPCA, IN ADENOCARCINOMAS AND PRECANCEROUS LESIONS IN THE PROSTATE
Uetsuki, H., Tsunemori, H., Taoka, R., Haba, R., Ishikawa, M., & Kakehi, Y. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000165154.41159.b1 · Cited by 77
Ananthanarayanan, V., Deaton, R., Yang, X. J., Pins, M. R., & Gann, P. H. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-73 · Cited by 76
Mammalian NDR protein kinases: From regulation to a role in centrosome duplication
Hergovich, A., Cornils, H., & Hemmings, B. A. (2007) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.07.017 · Cited by 83
Monamì, G., Emiliozzi, V., Bitto, A., Lovat, F., Xu, S., Goldoni, S., Fassan, M., Serrero, G., Gomella, L. G., Baffa, R., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080735 · Cited by 76
Ren, B., Yu, Y. P., Tseng, G. C., Wu, C., Chen, K., Rao, U. N. M., Nelson, J. B., Michalopoulos, G. K., & Luo, J. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk199 · Cited by 75
Self-citationIdentification and Regulation of a Molecular Module for Bleb-Based Cell Motility
Goudarzi, M., Banisch, T. U., Mobin, M. B., Maghelli, N., Tarbashevich, K., Strate, I., van den Berg, J., Blaser, H., Bandemer, S., Paluch, E. K., et al. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.05.007 · Cited by 75
Frigo, D. E., Sherk, A. B., Wittmann, B. M., Norris, J. D., Wang, Q., Joseph, J. D., Toner, A. P., Brown, M. A., & McDonnell, D. P. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0010 · Cited by 75
Pinto, F., Pértega‐Gomes, N., Pereira, M. S., Vizcaino, J. R., Monteiro, P., Henrique, R., Baltazar, F., Andrade, R. P., & Reis, R. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0421 · Cited by 74
NUSAP1 promotes invasion and metastasis of prostate cancer
Gordon, C. A., Gong, X., Ganesh, D., & Brooks, J. D. (2017) · Oncotarget · doi:10.18632/oncotarget.15604 · Cited by 74
Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer
Caino, M. C., Seo, J. H., Wang, Y., Rivadeneira, D. B., Gabrilovich, D. I., Kim, E. T., Weeraratna, A. T., Languino, L. R., & Altieri, D. C. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93172 · Cited by 79
The potential value of microseminoprotein‐β as a prostate cancer biomarker and therapeutic target
Whitaker, H. C., Warren, A. Y., Eeles, R. A., Kote‐Jarai, Z., & Neal, D. E. (2009) · The Prostate · doi:10.1002/pros.21059 · Cited by 78
Unveiling the potential of prohibitin in cancer
Koushyar, S., Jiang, W. G., & Dart, D. A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.09.012 · Cited by 72
Deregulation of a Hox Protein Regulatory Network Spanning Prostate Cancer Initiation and Progression
Chen, J. L., Li, J., Kiriluk, K. J., Rosen, A. M., Paner, G. P., Antic, T., Lussier, Y. A., & Griend, D. J. V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0373 · Cited by 72
Parr, R. L., Dakubo, G. D., Crandall, K. A., Maki, J. N., Reguly, B., Aguirre, A. A., Wittock, R., Robinson, K., Alexander, J. S., Birch‐Machin, M. A., et al. (2006) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.050112 · Cited by 75
Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model
Wang, Z., Xu, D., Ding, H.-F., Kim, J., Zhang, J., Hai, T., & Yan, C. (2014) · Oncogene · doi:10.1038/onc.2014.426 · Cited by 71
Lee, Y. G., Nam, Y., Shin, K. J., Yoon, S., Park, W. S., Joung, J. Y., Seo, J. K., Jang, J., Lee, S., Nam, D., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.017 · Cited by 73
Wang, L. G., Johnson, E. M., Kinoshita, Y., Babb, J. S., Buckley, M. T., Liebes, L., Melamed, J., Liu, X., Kurek, R., Ossowski, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6017 · Cited by 73
Zhang, K., Zhao, H., Ji, Z., Zhang, C., Zhou, P., Wang, L., Chen, Q., Wang, J., Zhang, P., Chen, Z., et al. (2015) · Oncogene · doi:10.1038/onc.2015.184 · Cited by 75
Alinezhad, S., Väänänen, R., Mattsson, J., Li, Y., Tallgrén, T., Tong-Ochoa, N., Bjartell, A. S., Åkerfelt, M., Taimen, P., Boström, P. J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155901 · Cited by 69
Protein 4.1B suppresses prostate cancer progression and metastasis
Wong, S. Y., Haack, H., Kissil, J. L., Barry, M., Bronson, R. T., Shen, S. S., Whittaker, C. A., Crowley, D. G., & Hynes, R. O. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705499104 · Cited by 69
EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance
Zhang, Y., Linn, D. E., Liu, Z., Melamed, J., Tavora, F. R. F., Young, C. Y. F., Burger, A. M., & Hamburger, A. W. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0526 · Cited by 68
Biological impact of missing-value imputation on downstream analyses of gene expression profiles
Oh, S., Kang, D., Brock, G. N., & Tseng, G. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq613 · Cited by 71
Cheng, C., Wang, J., Xu, P., Zhang, K., Xin, Z., Zhao, H., Ji, Z., Zhang, M., Wang, D., He, Y., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00380-3 · Cited by 67
Moreno, C. S. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090657 · Cited by 72
STAMP2 increases oxidative stress and is critical for prostate cancer
Jin, Y., Wang, L., Qu, S., Sheng, X., Kristian, A., Mælandsmo, G. M., Pällmann, N., Yuca, E., Tekedereli, İ., Görgülü, K., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404181 · Cited by 77
Samuel, C. A., Landrum, M. B., McNeil, B. J., Bozeman, S. R., Williams, C. D., & Keating, N. L. (2014) · American Journal of Public Health · doi:10.2105/ajph.2014.302079 · Cited by 70
Humoral Response Profiling Reveals Pathways to Prostate Cancer Progression
Taylor, B. S., Pal, M. K., Yu, J., Laxman, B., Sundaram, S. K., Zhao, R., Menon, A., Wei, J. T., Nesvizhskii, A. I., Ghosh, D., et al. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700263-mcp200 · Cited by 66
Kim, Y., Yoon, H. Y., Kim, Y.-W., Kim, E., Kim, W., Kim, I. Y., & Kim, W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2817 · Cited by 66
INTEGRATIVE BIOLOGY OF PROSTATE CANCER PROGRESSION
Tomlins, S. A., Rubin, M. A., & Chinnaiyan, A. M. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100047 · Cited by 66
Differential expression of anterior gradient gene AGR2 in prostate cancer
Maresh, E. L., Mah, V. H., Alavi, M., Horvath, S., Bagryanova, L., Liebeskind, E. S., Knutzen, L. A., Zhou, Y. F., Chia, D., Liu, A. Y. C., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-680 · Cited by 65
Discovery of prostate cancer biomarkers by microarray gene expression profiling
Sørensen, K. D., & Orntoft, T. F. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.74 · Cited by 65
Muders, M. H., Zhang, H., Wang, E., Tindall, D. J., & Datta, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0552 · Cited by 65
Han, Y., Zheng, Z., Zuo, Z., Yu, Y. P., Chen, R., Tseng, G. C., Nelson, J. B., & Luo, J. (2013) · The Journal of Pathology · doi:10.1002/path.4169 · Cited by 64
Self-citationHurley, P. J., Marchionni, L., Simons, B. W., Ross, A. E., Peskoe, S. B., Miller, R. M., Erho, N., Vergara, I. A., Ghadessi, M., Huang, Z., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203525109 · Cited by 64
Bhusari, S. S., Yang, B., Kueck, J., Huang, W., & Jarrard, D. F. (2011) · The Prostate · doi:10.1002/pros.21379 · Cited by 64
The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer
Murphy, T. M., Perry, A. S., & Lawler, M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0208 · Cited by 64
Shtutman, M. S., Baig, M. S., Levina, E. M., Hurteau, G. J., Lim, C., Broude, E. V., Nikiforov, M. A., Harkins, T. T., Carmack, C. S., Ding, Y., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103842108 · Cited by 69
Lee, S., Poulogiannis, G., Pyne, S., Jia, S., Zou, L., Signoretti, S., Loda, M. F., Cantley, L. C., & Roberts, T. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005642107 · Cited by 67
Identification of recurrent fusion genes across multiple cancer types
Yu, Y., Liu, P., Nelson, J. B., Hamilton, R. L., Bhargava, R., Michalopoulos, G. K., Chen, Q., Zhang, J., Ma, D., Pennathur, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38550-6 · Cited by 71
Self-citationProstatic preneoplasia and beyond
Joshua, A. M., Evans, A., van der Kwast, T., Zieleńska, M., Meeker, A. K., Chinnaiyan, A. M., & Squire, J. A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.12.001 · Cited by 80
Zhang, Y., Ali, T. Z., Zhou, H., D’Souza, D. R., Lu, Y., Jaffe, J. T., Liu, Z., Passaniti, A., & Hamburger, A. W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2904 · Cited by 62
Metadata
- Authors
- Yu, Y. P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., McDonald, C., Thomas, R., Dhir, R., Finkelstein, S., Michalopoulos, G., Becich, M., & Luo, J.-H.
- Affiliations
- University of Pittsburgh (US)
- From the Department of Pathology and Urology, University of Pittsburgh School of Medicine, and Biostatistics Center, University of Pittsburgh Cancer Institute and Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-15
- Volume
- 22
- Issue
- 14
- Pages
- 2790-2799
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2108426942
- Semantic Scholar
- 8be3bd0e253d2a736b72002f40143dec896e862a
- Cited by
- 758
- References
- 23
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 31 · 2023: 31 · 2022: 20 · 2021: 30 · 2020: 26 · 2019: 29 · 2018: 29 · 2017: 38 · 2016: 24 · 2015: 47 · 2014: 58 · 2013: 41 · 2012: 47
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U01CA088110, 1U01 CA 88110-01, R01CA098249)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- prostate cancer, gene expression profiling, tumor aggressiveness, prostate carcinogenesis, gene expression patterns
- MeSH terms
- Adult, Cell Transformation, Neoplastic, Humans, Male, Middle Aged, Neoplasm Invasiveness, Predictive Value of Tests, Prostate, Prostatic Neoplasms, Gene Expression, Disease Progression, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.